# Multifunctional Cu-doped Mn3O4 nanozyme hydrogel microspheres for oral targeted treatment of inflammatory bowel disease

**Authors:** Wei Fan, Yinyin Chen, Wenshuang Chen, Zisong Gao, Zhongke Yang, Hongyan Li, Aimin Wu, Xianxiang Wang

PMC · DOI: 10.1016/j.mtbio.2026.102932 · 2026-02-13

## TL;DR

Researchers developed a new oral treatment for inflammatory bowel disease using nanozyme hydrogel microspheres that target the colon and reduce inflammation.

## Contribution

A colon-targeted hydrogel microsphere system with Cu-doped Mn3O4 nanozymes for oral IBD treatment was engineered.

## Key findings

- HMCM effectively scavenges ROS and exhibits SOD, CAT, and GPx-like activities.
- HMCM reduces inflammation, enhances antioxidant activity, and inhibits ferroptosis in colonic tissue.
- HMCM restores gut microbiota balance and shows high biosafety and colon-specific retention.

## Abstract

Oral drug therapy for inflammatory bowel disease (IBD) is often hindered by inadequate targeting, low bioavailability, and reactive oxygen species (ROS) accumulation. To address these challenges, we have developed hydrogel microspheres@Cu-Mn3O4 nanozymes (HMCM) by encapsulating hydrothermally synthesized Cu-doped Mn3O4 nanozymes (CM NZs) into calcium alginate hydrogel microspheres (HM) using microfluidics. These microspheres are designed for colon-targeted IBD treatment. The CM NZs exhibit exceptional superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activities, effectively scavenging ROS such as H2O2, ·OH, and O2−·. The negatively charged HMCM promotes targeted accumulation in inflamed colon regions and facilitates specific nanozyme release. In a dextran sulfate sodium (DSS)-induced colitis mouse model, HMCM administration enhanced the expression of tight junction proteins (Claudin, ZO-1, Occludin) and repaired the damaged intestinal barrier. The oral HMCM group significantly reduced inflammation, enhanced antioxidant activity, and inhibited ferroptosis in colonic tissue through the upregulation of GPX4 and SLC7A11. It also restored gut microbiota balance by increasing probiotic populations and suppressing harmful bacteria. Systemic biosafety assessments confirmed HMCM's colon-specific retention and high biocompatibility. This research establishes HMCM as a precision-targeted colonic drug delivery platform, offering a promising therapeutic strategy for the treatment of inflammatory bowel disease.

Calcium alginate hydrogel microspheres @ Cu-Mn3O4 nanozymes (HMCM) were successfully synthesized. Due to their negatively charged surface, HMCM achieves site-specific enrichment in the colon and releases Cu-Mn3O4 nanozymes (CM NZs), which exhibit antioxidant enzyme-like activity and reactive oxygen species (ROS) scavenging capacity. In a DSS-induced colitis mouse model, HMCM effectively treated IBD through a triple synergistic mechanism: enhancing antioxidant and anti-inflammatory activities, inhibiting ferroptosis in colonic tissue cells, and regulating gut microbiota. This work presents an efficient, targeted strategy for IBD therapy.Image 1

•The synthesized Cu-Mn3O4 nanozymes (CM NZs) exhibit stronger multi-enzyme mimicking activities (SOD, CAT, GPx) and free radical scavenging ability compared to Mn3O4 NPs.•A colon-targeted composite of hydrogel microspheres@Cu-Mn3O4 nanozymes (HMCM) was engineered for precise oral nanozyme delivery.•HMCM treats IBD via a triple-synergistic mechanism. It simultaneously reduces inflammation and oxidative stress, inhibits ferroptosis by upregulating the GPX4/SLC7A11 pathway, and beneficially reshapes the gut microbiota, collectively restoring intestinal homeostasis.•HMCM demonstrates excellent systemic biosafety and colon-specific retention.

The synthesized Cu-Mn3O4 nanozymes (CM NZs) exhibit stronger multi-enzyme mimicking activities (SOD, CAT, GPx) and free radical scavenging ability compared to Mn3O4 NPs.

A colon-targeted composite of hydrogel microspheres@Cu-Mn3O4 nanozymes (HMCM) was engineered for precise oral nanozyme delivery.

HMCM treats IBD via a triple-synergistic mechanism. It simultaneously reduces inflammation and oxidative stress, inhibits ferroptosis by upregulating the GPX4/SLC7A11 pathway, and beneficially reshapes the gut microbiota, collectively restoring intestinal homeostasis.

HMCM demonstrates excellent systemic biosafety and colon-specific retention.

## Linked entities

- **Genes:** GPX4 (glutathione peroxidase 4) [NCBI Gene 2879], SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657], cldn10e (claudin 10e) [NCBI Gene 556021], TJP1 (tight junction protein 1) [NCBI Gene 7082], si:ch73-61d6.3 (uncharacterized si:ch73-61d6.3) [NCBI Gene 103182021]
- **Diseases:** inflammatory bowel disease (MONDO:0005265), colitis (MONDO:0005292)

## Full-text entities

- **Genes:** Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Slc17a5 (solute carrier family 17 (anion/sugar transporter), member 5) [NCBI Gene 235504] {aka 4631416G20Rik, 4732491M05, AST, ISSD, NSD, SD}, Prdx6-ps2 (peroxiredoxin 6 pseudogene 2) [NCBI Gene 384001] {aka Aop2-rs2, GPx*, Prdx6-rs2}, Slc3a2 (solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2) [NCBI Gene 17254] {aka 4F2, 4F2HC, Cd98, Ly-10, Ly-m10, Ly10}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Gpx4 (glutathione peroxidase 4) [NCBI Gene 625249] {aka GPx-4, GSHPx-4, PHGPx, mtPHGPx, snGPx}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Nlrp3 (NLR family, pyrin domain containing 3) [NCBI Gene 216799] {aka AGTAVPRL, AII/AVP, Cias1, FCAS, FCU, MWS}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Slc7a11 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 11) [NCBI Gene 26570] {aka 9930009M05Rik, sut, xCT}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, Ocln (occludin) [NCBI Gene 18260] {aka Ocl}
- **Diseases:** IBD (MESH:D015212), enteritis (MESH:D004751), ulcerative colitis (MESH:D003093), inflammatory colon disease (MESH:D003108), intestinal injury (MESH:D007410), Cytotoxicity (MESH:D064420), weight loss (MESH:D015431), Colitis (MESH:D003092), diarrhea (MESH:D003967), fatigue (MESH:D005221), weight gain (MESH:D015430), hemolysis (MESH:D006461), inflammation (MESH:D007249), abdominal pain (MESH:D015746), rectal bleeding (MESH:D012002), dysbiosis (MESH:D064806)
- **Chemicals:** OH (MESH:C031356), lipid (MESH:D008055), ABTS (MESH:C002502), LPS (MESH:D008070), GSH (MESH:D005978), DSS (MESH:D016264), CM (MESH:D003476), berberine (MESH:D001599), Cy5 (MESH:C085321), ROS (MESH:D017382), Mn (MESH:D008345), PBS (MESH:D007854), luteolin (MESH:D047311), Pluronic F-127 (MESH:D020442), H&amp;E (MESH:D006371), (N)  OH (-), H2O2 (MESH:D006861), MDA (MESH:D008315), oil (MESH:D009821), K2S2O8 (MESH:C009007), TA (MESH:C011363), magnolol (MESH:C005498), iron (MESH:D007501), MB (MESH:D008751), water (MESH:D014867), CCK-8 (MESH:D012844), MnO2 (MESH:C016552), borneol (MESH:C022871), glycyrrhizic acid (MESH:D019695), hyaluronic acid (MESH:D006820), ethanol (MESH:D000431), -Mn3O4 (MESH:C027424), Cu (MESH:D003300), acetic acid (MESH:D019342), BODIPY (MESH:C095489), CaCl2 (MESH:D002122), O (MESH:D010100), Calcium alginate (MESH:D000464), chitosan (MESH:D048271), PI (MESH:D010716), Prussian blue (MESH:C000170), 5-ASA (MESH:D019804), saline (MESH:D012965), T- (MESH:D014316), Fer-1 (MESH:C573944), Calcein-AM (MESH:C085925), Cu (CH3COO)2 (MESH:C015092), H2DCFDA (MESH:C110400), DPPH (MESH:C004931), EDTA (MESH:D004492)
- **Species:** Shigella (genus) [taxon 620], gut metagenome (species) [taxon 749906], Stenotrophomonas maltophilia (species) [taxon 40324], Odoribacter (genus) [taxon 283168], Homo sapiens (human, species) [taxon 9606], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Pseudomonadota (proteobacteria, phylum) [taxon 1224], Actinomycetota (actinobacteria, phylum) [taxon 201174], Escherichia coli (E. coli, species) [taxon 562], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** A2A, S12M
- **Cell lines:** MCEC — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_B288), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU), Hep — Homo sapiens (Human), Cervical carcinoma, Cancer cell line (CVCL_JB76), /6 — Homo sapiens (Human), Tongue squamous cell carcinoma, Cancer cell line (CVCL_5985), RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), HMCM — Mus musculus (Mouse), Hybridoma (CVCL_C0PK)

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12924754/full.md

---
Source: https://tomesphere.com/paper/PMC12924754